Wednesday tips round-up: Tesco, SSL International, AstraZeneca
Tesco has punchy capex plans. This year it will spend £4.2bn on capex, equivalent to 8pc of its sales. This figure is far bigger than a sector average of 4.5pc of sales. However, Tesco is far bigger than rivals. Analysts expect low double digit EPS growth to continue. Buy, says the Telegraph.
SSL International shares have fallen from a high of 564½p in January amid fears of a consumer slowdown. At 450½p, up 9¼p yesterday, the sell-off may now seem overdone. Buy, says the Times. The Independent agrees and also says buy.
Investors normally find sanctuary in drug companies when the market and the economy hit troubled waters. This hasn't happened this time. It seems that instead of looking for the outside world to help them out, the big pharma companies will need to do it themselves.
With new products due to come on stream and income from Nexium secured for a few more years, AstraZeneca may be starting to do just that. Progress will probably not be fast but the Telegraph thinks the shares are worth buying.
(Article continues below)Advertisement
At 115p, off 20p yesterday, Chrysalis shares are still up from this year's low of 97½p amid hopes that a sale may yet materialise. Yet debt markets are likely to remain shut for the rest of the year. Investors may be in for a long wait for recovery. Take profits, writes the Times.
As a retailer Burberry is a very good punt; however, given that few investors have to be exposed to the sector, most buyers should think carefully about the stock. Retailers from every walk of life will have a tricky 2008, and it is unlikely that any will come out unscathed. Cautious hold, says the Independent.
Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
